Clinical Data — BMO Capital Markets Focus on Healthcare Conference 2009
30 slides from Clinical Data's conference presentation, Aug 5, 2009

Slide 1: BMO Capital Markets Focus on Healthcare Conference
1 BMO Capital Markets Focus on Healthcare Conference August 5, 2009

Slide 2: Forward-Looking Statement
Forward-Looking Statement 2 This presentation contains certain forward-looking information about Clinical Data that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements a

Slide 3: Investment Opportunity
Investment Opportunity Clinical Data is a biotechnology company developing late-stage drugs that are first-in-class, best-in-category, or both 3 Central Nervous System Cardiovascular Disease Oncology

Slide 4: Current Value Drivers
Current Value Drivers Two Phase III drugs: Vilazodone(tm): first-in-class dual acting serotonergic antidepressant Stedivaze(tm): potential best-in-class drug used as a vasodilator for cardiac stress testing Deep pipeline of drugs and biomarkers candidates Genetic testing business for inherited cardi

Slide 5: Vilazodone: New Options Needed in the Treatment of Depression
Vilazodone: New Options Needed in the Treatment of Depression Common chronic condition affects approximately 18M U.S. Leading cause of disability in U.S. for ages 15-44 Majority of patients do not achieve success with 1st therapy Side effects are common Certain side effects influence prescribing mor

Slide 6: Vilazodone for Treatment of Depression
Vilazodone for Treatment of Depression First-in-class antidepressant with a dual serotonergic mechanism of action SSRI 5HT1A Demonstrated superiority to placebo in 2 Phase III trials Well-tolerated with low discontinuation rate Sexual function is similar to placebo as measured by validated scales Op

Slide 7: Summary of Development Program
Summary of Development Program 2/2 positive Phase III pivotal* trials Industry average for depression trials is ~50% Efficacy claim will be based on pivotal trials at 40mg QD Total database of >2,200 patients including long-term exposure Completed studies required for NDA submission including ECG ef

Slide 8: Summary of Phase III Pivotal Trials
Summary of Phase III Pivotal Trials Patients 18-70 years of age with moderate to severe depression Primary endpoint change from baseline to week 8 in MADRS score, ITT/LOCF Baseline MADRS score of 31 Secondary endpoints HAMD, HAMA Day 0 10 mg Week 1 20 mg Week 2 40 mg Week 8 8

Slide 9: Low Discontinuation Rates in Phase III Studies
Low Discontinuation Rates in Phase III Studies 9 1st Phase III Trial 1st Phase III Trial 2nd Phase III Trial 2nd Phase III Trial Vilazodone Placebo Vilazodone Placebo Enrolled 205 205 240 241 Discontinued 53 (25.9%) 51 (24.9%) 47 (19.6%) 46 (19.1%) Adverse Event 19 (9.3%) 10 (4.9%) 12 (5.1%) 4 (1.7%

Slide 10: 2nd Phase III Trial Confirms Superiority to Placebo
2nd Phase III Trial Confirms Superiority to Placebo 10 Least Squares Mean Change at Week 8 Least Squares Mean Change at Week 8 LS Mean Treatment Difference p-value 1st Phase III Vilazodone N = 198 Placebo N = 199 MADRS -12.9 -9.6 -3.2 0.001 HAMD17 -10.4 -8.6 -1.7 0.022 HAMA -6.5 -5.2 -1.4 0.031 2nd

Slide 11: Adverse event comparison with marketed antidepressants
Zoloft(r) (sertraline hydrochloride)* Zoloft(r) (sertraline hydrochloride)* Zoloft(r) (sertraline hydrochloride)* AE Drug Placebo Nausea 26% 12% Diarrhea/ loose stools 18% 9% Somnolence 13% 6% Tremor 11% 3% Sweating Increased 8% 3% Ejaculation failure 7% <1% Dyspepsia 6% 3% Vilazodone Phase III Tria

Slide 12: Sexual Dysfunction is Common in Depression
Sexual Dysfunction is Common in Depression 40 to 50% of depressed patients report sexual dysfunction1 Drug-induced SD is common with antidepressants SSRI use results in 25-80% incidence of drug-induced sexual dysfunction2 Up to 90% of patients who experience antidepressant-induced sexual dysfunction

Slide 13: Vilazodone Impact on Overall Sexual Function Comparable to Placebo
Vilazodone Impact on Overall Sexual Function Comparable to Placebo 13 Change from Baseline in CSFQ Total Score Change from Baseline in CSFQ Total Score Change from Baseline in CSFQ Total Score Change from Baseline in CSFQ Total Score Change from Baseline in CSFQ Total Score Change from Baseline in C

Slide 14: Long Term Exposure Study Complete for NDA Submission
Long Term Exposure Study Complete for NDA Submission 1 year, open label treatment study Regulatory minimum requirement is 300 patients on drug for 6 months and 100 patients for 12 months 2 week titration to 40 mg QD Baseline HAMD17 ^ 18 Results were consistent with pivotal trials which demonstrated

Slide 15: Regulatory Approval of Antidepressants
Regulatory Approval of Antidepressants FDA requires demonstration of: Acceptable risk/benefit ratio Statistical significance in two adequately powered controlled trials Robust results on multiple measures using multiple analytic methods (MADRS, HAMD, CGI) Safety in both acute and chronic administrat

Slide 16: Commercial Opportunity for Vilazodone in the Treatment of Depression
Commercial Opportunity for Vilazodone in the Treatment of Depression 16

Slide 17: Depression is Largest Segment of CNS Market
Depression is Largest Segment of CNS Market U.S. market continues to grow1 $12B annual sales 208M+ prescriptions Medical cost to treat depression is close to $30B annually2 Vilazodone relevant market SSRIs (i.e. Zoloft(r), Lexapro(r), Celexa(r), Prozac(r)) SNRIs (i.e. Cymbalta(r), Effexor(r)XR, Pris

Slide 18: Prescriptions Increasing at 4% CAGR
Prescriptions Increasing at 4% CAGR* 18 * IMS Health's National Prescription Audit Year Includes SSRIs, SNRIs, and Wellbutrin

Slide 19: Depression Market is Highly Concentrated to Top Prescribers
Market Decile Number of Prescribers Minimum TRx Maximum TRx Average TRx Cum. % of Prescribers Cum. % of TRx 10 3,517 3,545 28,320 5,123 0.5% 10.0% 9 6,437 2,342 3,545 2,800 1.5% 20.0% 8 8,890 1,792 2,341 2,027 2.9% 30.0% 7 11,245 1,445 1,792 1,603 4.7% 40.0% 6 13,864 1,174 1,445 1,300 6.8% 50.0% 5 1

Slide 20: Primary Market Research Confirms Opportunity
Primary Market Research Confirms Opportunity Quantitative, primary market research with PCPs & Psychiatrists 50% of time physicians do not achieve desired results with first therapy Tolerability is often the reason for patient discontinuations 60% of physicians felt lack of sexual dysfunction was ex

Slide 21: Depression Drugs Compete in Generic Market
Depression Drugs Compete in Generic Market 21 Quarterly Sales 2003 - 2008 IMS HEALTH'S National Sales Perspective Celexa(r) goes generic (Q4'04) Zoloft(r) goes generic (Q3'06)

Slide 22: Market Share Driven By Many Factors
Market Share Driven By Many Factors* 22 * N Engl J Med 2008;358:252-60. Based on FDA threshold for measuring effect size ** Clinical Data Inc. Phase III Registration Trial Results ^ 2008 IMS HEALTH'S National Sales Perspective Vilazodone has not been approved by FDA. Clinical Data is making no claim

Slide 23: Vilazodone Addresses Unsatisfied Market
Vilazodone Addresses Unsatisfied Market Physicians/patients continue to seek new options Vilazodone's unique mode of action and safety/tolerability profile provide significant differentiation Favorable physician acceptance in market research1 Received a 7/10 rating Over 60% would probably or definit

Slide 24: Stedivaze: Vasodilator for Cardiac Stress Testing
Stedivaze: Vasodilator for Cardiac Stress Testing Stedivaze: Vasodilator for Cardiac Stress Testing 24 1 AMR Monthly Monitor

Slide 25: Stedivaze Clinical Development Program
Stedivaze Clinical Development Program Decision to pause the start of Phase III trials Insights gained from July 28, 2009 FDA Advisory Board meeting Revising trial protocol to reflect recent feedback Initiated Phase I studies in chronic obstructive pulmonary disease and asthma to demonstrate safety

Slide 26: Therapeutics Pipeline
Therapeutics Pipeline Current Stage Lead Discovery Preclinical Phase I Phase II Phase III NDA Marketed Novartis Confidential Partner Vilazodone(tm) Major Depression Stedivaze(tm) Cardiac Imaging ATL1222: Acute Inflammation ATL844: Diabetes / Asthma ATL313 : Ophthalmic Pain AVN316: Oncology Projected

Slide 27: Dx for Inherited Cardiac Conditions: FAMILION
Dx for Inherited Cardiac Conditions: FAMILION(r) Over 100% Growth Year Over Year* *Calendar Year 0 ..5 1 1.5 2 2.5 2004 2005 2006 2007 2008 New Sales Force $ (Millions) $3 2009 27

Slide 28: Clinical Data (CLDA) Profile
Clinical Data (CLDA) Profile* 28 Revenue: $ 3.2M (3 mo.) $10.4M (Year end) Cash & Marketable Securities: $56.4M $15.6M Sale of Cogenics business (4/15) Debt: $53.2M** Shares Outstanding: 23.7M Insider Ownership: ~ 50% Substantially all shares purchased *As of 3/31/09 unless otherwise indicated **Net

Slide 29: Upcoming Events in 2009
Upcoming Events in 2009 Submit vilazodone NDA to the FDA Continue preparations for commercialization Complete Phase I studies for Stedivaze in COPD and asthma; start Phase III program in 2H 2009 Establish partnerships for other preclinical programs Continue to grow genetic testing business 29

Slide 30: Thank You
os — fa 4 = u Fiom Tifgeted Science if & Ye to Beiter Healthcare™ & & , ie y | CLINICAL Thank You
Source: SEC EDGAR · 8-K filed Aug 5, 2009
More decks from Clinical Data Inc
J. P. Morgan Healthcare Conference 201127 slides · Jan 12, 2011
Technical Presentation (May 2010)10 slides · May 25, 2010
Rodman & Renshaw Global Investment Conference 200924 slides · Sep 9, 2009
Fifth Annual Noble Financial Equity Conference 200923 slides · Jun 9, 2009
Investor Presentation (January 2009)25 slides · Jan 12, 2009
BMO Capital Markets Focus On Healthcare Conference 200833 slides · Aug 5, 2008